# Vaccinia Virus Vector Bivalent Norovirus Vaccine

## TL;DR

Researchers developed a bivalent norovirus vaccine using a modified poxvirus vector that can potentially protect against two major norovirus strains.

## Contribution

A bivalent norovirus vaccine based on a highly attenuated poxvirus vector is proposed for broad-spectrum protection.

## Key findings

- VG9-NOR induced high IgG and IgA antibody titers against GII.4 and GII.17 in mice.
- VG9-NOR enhanced GII.4 and GII.17-specific HGBA-blocking antibodies and mucosal immunity.
- VG9-NOR triggered a Th1-mediated cellular immune response.

## Abstract

Norovirus is a major etiological agent of nonbacterial gastroenteritis around the world. Due to its in vitro culture complexity, high genome diversity, and the lack of cross-reactive immunity between genogroups, there is an unmet urgent need for polyvalent norovirus vaccines that provide broad-spectrum protection, and no vaccine has gained global approval to date. In this study, we constructed a bivalent norovirus vaccine, based on the highly attenuated poxvirus [strain VG9] vector, expressing the major capsid protein VP1 from genotypes GII.4 and GII.17. VG9-NOR exhibited a comparable replication ability to the authentic virus while preserving good safety. After the intramuscular and intranasal immunization of mice, VG9-NOR induced high IgG- and IgA-binding antibody (Ab) titers against GII.4 and GII.17, increased the secretion of GII.4 and GII.17-specific HGBA-blocking antibodies, and enhanced GII.17-specific mucosal immunity. Furthermore, VG9-NOR also induced a Th1-mediated cellular response. These results demonstrate that the polyvalent poxvirus vector vaccine expressing VP1 variants from different subtypes is able to elicit effective protection. Our study highlights the VG9 vector as a highly promising candidate for the development of polyvalent norovirus vaccines.